Heat Biologics Inc (NASDAQ:HTBX) has appointed Dr. Jeff Hutchins as its Chief Operating Officer. Dr. Hutchins was previously CSO and SVP, Pre-clinical Development with the company. In his new role, he will lead product development initiatives for Heat Biologic and its Pelican Therapeutics subsidiary firm.
The management view
Jeff Wolf, the CEO of Heat Biologics, reported that Dr. Hutchins has played a vital role in company’s evolution and has been an important member of their executive team. He is an accomplished biotech executive and talented scientist, and his expertise and vision should help them accelerate their clinical activities on the basis of the most recent promising clinical data in their underway Phase II clinical study of HS-110 together with Bristol-Myers Squibb Co (NYSE:BMY)‘s anti-PD-1 checkpoint inhibitor, Opdivo®, for the treatment of NSCLC.
Commenting on his new role, Dr. Hutchins said that it is a thrilling time to be at Heat and he is honored to take the responsibility of supervising its product development initiatives. His objective in this new role is to advance their unique product pipeline to the marketplace as efficiently and rapidly as possible. He looks forward to advancing to work with an extremely talented team to progress their thrilling Phase II lung cancer clinical study in combination with nivolumab. They are motivated by the industry response following the promising interim data they announced earlier this year, and anticipate releasing additional data later in 2017.
Dr. Hutchins has R&D experience of more than 24 years from both biotechnology and pharmaceutical firms. Prior to joining Heat Biologics, he was VP of Pre-clinical Research at Peregrine Pharmaceuticals (NASDAQ:PPHM) and VP of Pre-clinical Development for Inhibitex Inc., which was later bought by Bristol-Myers Squibb.
Heat Biologics also released an update from the Annual Meeting of Shareholders, wherein it restated that the company has no immediate plans to opt for a reverse split. The plan, as adopted in preceding years, was a preventive measure for corporate governance purposes and to offer the board with extreme flexibility. Wolf stated that the approved resolutions provide them with the flexibility required for good corporate governance.